Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANRO 
Alto Neuroscience, Inc. (ANRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ANRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.33
1 Year Target Price $10.33
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -85.78% | Avg. Invested days 18 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 103.16M USD | Price to earnings Ratio - | 1Y Target Price 10.33 |
Price to earnings Ratio - | 1Y Target Price 10.33 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 1.60 - 15.04 | Updated Date 08/29/2025 |
52 Weeks Range 1.60 - 15.04 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.6 | Actual -0.65 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.72% | Return on Equity (TTM) -42.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -17114044 | Price to Sales(TTM) - |
Enterprise Value -17114044 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 27076600 | Shares Floating 17884113 |
Shares Outstanding 27076600 | Shares Floating 17884113 | ||
Percent Insiders 7.48 | Percent Institutions 64.06 |
Upturn AI SWOT
Alto Neuroscience, Inc.
Company Overview
History and Background
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for mental health. Founded to address the significant unmet need in treating mental illnesses by leveraging neurobiological data to identify patients most likely to respond to specific treatments.
Core Business Areas
- Drug Development: Focuses on the research, development, and clinical trials of novel therapeutics for various mental health conditions.
- Precision Psychiatry Platform: Utilizes brain biomarkers, such as EEG activity and cognitive assessments, to identify patient subgroups and predict treatment response.
Leadership and Structure
The leadership team includes experienced professionals in drug development, neuroscience, and business management. The company's structure includes research and development, clinical operations, and commercial strategy divisions.
Top Products and Market Share
Key Offerings
- ALTO-100: A novel compound in clinical development for major depressive disorder (MDD). Market share is currently N/A as it's not yet approved. Competitors include SSRIs and other antidepressants from companies like Eli Lilly (LLY) and Pfizer (PFE).
- ALTO-203: Being developed for PTSD. Market share is N/A, as it is in clinical trials. Competitors include drugs from companies like Bausch Health Companies (BHC) and generic versions of existing treatments.
Market Dynamics
Industry Overview
The mental health therapeutics market is large and growing, driven by increased awareness, diagnosis rates, and the need for more effective treatments. There's a growing emphasis on precision medicine approaches to improve treatment outcomes.
Positioning
Alto Neuroscience is positioned as a leader in precision psychiatry, using biomarkers to develop targeted therapies. This differentiates them from traditional pharmaceutical companies that rely on a broader approach.
Total Addressable Market (TAM)
The global mental health market is estimated at hundreds of billions of dollars. Alto Neuroscience is positioned to capture a significant share of this market by developing more effective and targeted treatments.
Upturn SWOT Analysis
Strengths
- Proprietary precision psychiatry platform
- Strong focus on biomarker-driven drug development
- Experienced management team
- Pipeline of novel drug candidates
Weaknesses
- Clinical trial risks
- High R&D expenses
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of the precision psychiatry platform to other therapeutic areas
- Increased adoption of biomarker-based diagnostics
- Growing demand for personalized mental health treatments
Threats
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- Eli Lilly (LLY)
- Pfizer (PFE)
- Bausch Health Companies (BHC)
Competitive Landscape
Alto Neuroscience differentiates itself through its precision psychiatry approach. Competitors have established products and market share, but Alto's focus on biomarkers may provide a competitive advantage in the long run.
Growth Trajectory and Initiatives
Historical Growth: N/A due to limited operating history as a public entity.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals. Analyst estimates will become available post-IPO.
Recent Initiatives: Focusing on advancing its clinical pipeline, securing partnerships, and expanding its precision psychiatry platform.
Summary
Alto Neuroscience is a promising clinical-stage company focused on precision psychiatry, leveraging biomarkers for targeted mental health treatments. Its success hinges on positive clinical trial results and regulatory approvals. The company faces competition from established pharmaceutical players but has a unique approach that could drive future growth and requires funding to sustain.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- ClinicalTrials.gov
- SEC Filings (Post IPO)
Disclaimers:
This analysis is based on currently available information and is subject to change. Market share data are estimates. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alto Neuroscience, Inc.
Exchange NYSE | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2024-02-02 | Founder, Chairman of the Board, CEO & President Dr. Amit Etkin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 76 | Website https://www.altoneuroscience.com |
Full time employees 76 | Website https://www.altoneuroscience.com | ||
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.